RTTNews | Dec 21, 2021 08:02AM EST

08:01 Tuesday, December 21, 2021 (RTTNews.com) - Mind Medicine (MindMed) Inc. (MNMD) said the FDA has placed a clinical hold on its IND submission intended to support the initiation of a phase 2b trial of lysergic acid diethylamide for the treatment of generalized anxiety disorder.

Robert Barrow, CEO of MindMed, said: "We remain highly confident in the therapeutic potential of lysergic acid diethylamide to usher in a new treatment paradigm for these disorders and we look forward to working closely with FDA to satisfy all outstanding concerns as rapidly as possible."

MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies.

Shares of MindMed were down 7% in pre-market trade on Tuesday.

Read the original article on RTTNews ( https://www.rttnews.com/3250824/mindmed-fda-issues-clinical-hold-on-initial-ind-submission-related-to-phase-2b-trial-of-lsd.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved